• Aimed Bio expects a milestone payment under its ODS025 licensing agreement with Boehringer Ingelheim, signed Oct. 15, 2025.
• The payment represents at least 10% of 2025 consolidated revenue of approximately KRW 47.3 billion.
• Milestone confirmation arrived Oct. 26, 2026; payment is expected within 45 days of Boehringer Ingelheim receiving the invoice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aimed Bio Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027900002), on October 27, 2026, and is solely responsible for the information contained therein.